Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.

A number of other brokerages have also weighed in on AUPH. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Down 0.2 %

NASDAQ AUPH traded down $0.02 during mid-day trading on Friday, reaching $8.32. 2,228,163 shares of the company’s stock traded hands, compared to its average volume of 1,609,360. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.05. The company has a fifty day simple moving average of $7.13 and a 200-day simple moving average of $6.11. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -24.47 and a beta of 1.45.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The firm had revenue of $67.77 million during the quarter, compared to analyst estimates of $59.07 million. As a group, equities research analysts expect that Aurinia Pharmaceuticals will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC acquired a new position in Aurinia Pharmaceuticals during the 2nd quarter valued at approximately $1,713,000. Cetera Advisors LLC boosted its position in Aurinia Pharmaceuticals by 18.9% during the 1st quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 9,547 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Aurinia Pharmaceuticals by 15.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 5,079 shares during the period. Vanguard Group Inc. boosted its position in Aurinia Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after purchasing an additional 21,119 shares during the period. Finally, SG Americas Securities LLC boosted its position in Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after purchasing an additional 535,301 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.